


McHarry

Feb 6 1998
BIOTECHNOLOGY
SYSTEMS
BRANCH



#8

chh
6-5-98

RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 08/822963
Art Unit / Team No. : 1635
Date Processed by STIC: 5/5/98

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,**
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY**

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963

DATE: 05/05/98
TIME: 14:45:52

INPUT SET: S25541.raw

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

Does Not Comply
Corrected Diskette Needed

SEQUENCE LISTING

1
2
3 (1) General Information
4
5 (i) APPLICANTS: ^{no 5} DAKAI LIU
6 RABBANI, ELAZAR
7
8 (ii) TITLE OF INVENTION: VECTORS AND VIRAL VECTORS, AND PACKAGING CELL LINES FOR (PRO)
9
--> 10 (iii) NUMBER OF SEQUENCES: 16 "16" are shown - do not
11 place dashes
12 (iv) CORRESPONDENCE ADDRESS: before or after
13 (A) ADDRESSEE: ENZO THERAPEUTICS, INC. numeric
14 (B) STREET: C/O ENZO BIOCHEM, INC. total;
15 527 MADISON AVENUE, 9TH FLOOR just use 16
16 (C) CITY: NEW YORK
17 (D) STATE: NY
18 (E) COUNTRY: USA
19 (F) ZIP: 10022
20
21 (v) COMPUTER READABLE FORM:
22 (A) MEDIUM TYPE: 3.5" Micro Floppy Disk. 1.44 KB
23 STORAGE
24 (B) COMPUTER: IBM PC/XT/AT, IBM PS/2 OR COMPATIBLES
25 (C) OPERATING SYSTEM: PC-DOS
26 (D) SOFTWARE: MICROSOFT WORD ____ - ASCII TEXT (DOS)
27
28 (vi) CURRENT APPLICATION DATA:
29 (A) APPLICATION NUMBER: US 08/822,963
30 (B) FILING DATE: 21-MARCH-1997
--> 31 (C) CLASSIFICATION: Not Yet Known
32
33 (vii) ATTORNEY/AGENT INFORMATION;
34 (A) NAME: FEDUS, RONALD C.
35 (B) REGISTRATION NUMBER: 32,567
36 (C) REFERENCE/DOCKET NUMBER: ENZ-56
37
38 (viii) TELECOMMUNICATION INFORMATION
39 (A) TELEPHONE: (212) 583-0100
40 (B) TELEFAX: (212) 583-0150
41
--> 42 (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1: delete - does not belong here
43

ERRORED SEQUENCES FOLLOW:

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:45:53

INPUT SET: S25541.raw

--> 44 (2) INFORMATION FOR SEQ ID NO:1:
45 (i) SEQUENCE CHARACTERISTICS:
46 (A) LENGTH:9 base pairs
47 (B) TYPE:nucleic acid
48 (C) STRANDEDNESS:double
49 (D) TOPOLOGY:linear
50 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:1:

51
52 TATCAACGC
53 ATAGTGGCG
54
55
56
57
58

involved - Per 1.822 (j) of sequence
rules, a nucleotide sequence shall be
presented, only by a single strand,
in the 5' to 3' direction, from left to right

Per 1.822 (l) of
sequence rules,
cumulative base total
goes to right 96 - insert
margin of each line.

--> 59 (2) INFORMATION FOR SEQ ID NO:2:
60 (i) SEQUENCE CHARACTERISTICS:
61 (A) LENGTH:9 base pairs
62 (B) TYPE:nucleic acid
63 (C) STRANDEDNESS:double
64 (D) TOPOLOGY:linear
65 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:2:

66
67 ACAAGAAAA
68 TGTTCTTTT
69

same error
throughout listing

total

--> 70 (2) INFORMATION FOR SEQ ID NO:3:
71 (i) SEQUENCE CHARACTERISTICS:
72 (A) LENGTH:10 base pairs
73 (B) TYPE:nucleic acid
74 (C) STRANDEDNESS:double
75 (D) TOPOLOGY:linear
76 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:3:

77
78 GTACTAGTTA
79 CATGATCAAT
80

--> 81 (2) INFORMATION FOR SEQ ID NO:4:
82 (i) SEQUENCE CHARACTERISTICS:
83 (A) LENGTH:8 base pairs
84 (B) TYPE:nucleic acid
85 (C) STRANDEDNESS:double
86 (D) TOPOLOGY:linear
87 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:4:

88
89 AGACGTCT
90 TCTGCAGA
91

92 (2) INFORMATION FOR SEQ ID NO:5:

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:45:54

INPUT SET: S25541.raw

--> 93 (i) SEQUENCE CHARACTERISTICS:
94 (A) LENGTH:24 base pairs
95 (B) TYPE:nucleic acid
96 (C) STRANDEDNESS:double
97 (D) TOPOLOGY:linear
98 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:5:
99
100 TGG AATTGTGAGCGGATAACAATT
101 ACCTTAACACTCGCCTATTGTAA
102

insert label
also,
invalid - Per 1.822 (f) of Sequence Rules,
non-coding bases are divided into
groups of 10 bases.

103 (2) INFORMATION FOR SEQ ID NO:6:
104 (i) SEQUENCE CHARACTERISTICS:
--> 105 (A) LENGTH:4 base pairs
106 (B) TYPE:nucleic acid
107 (C) STRANDEDNESS:double
108 (D) TOPOLOGY:linear
109 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:6:
110
111 TAAT
112 ATTA
113

114 (2) INFORMATION FOR SEQ ID NO:7:
115 (i) SEQUENCE CHARACTERISTICS:
--> 116 (A) LENGTH:9 base pairs
117 (B) TYPE:nucleic acid
118 (C) STRANDEDNESS:double
119 (D) TOPOLOGY:linear
120 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:7:
121
122 CATGTAATT
123 GTACATTAA
124

125 (2) INFORMATION FOR SEQ ID NO:8:
126 (i) SEQUENCE CHARACTERISTICS:
--> 127 (A) LENGTH:13 base pairs
128 (B) TYPE:nucleic acid
129 (C) STRANDEDNESS:double
130 (D) TOPOLOGY:linear
131 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:8:
132
133 AAAAGTGTGACAT
134 TTTTCACACTGTA
135

136 (2) INFORMATION FOR SEQ ID NO:9:
137 (i) SEQUENCE CHARACTERISTICS:
--> 138 (A) LENGTH:11 base pairs
139 (B) TYPE:nucleic acid
140 (C) STRANDEDNESS:double
141 (D) TOPOLOGY:linear

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:45:55

INPUT SET: S25541.raw

142 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:9:
143
144 CCGGAGGACAG
145 GGCCTCCTGTC
146

--> 147 (2) INFORMATION FOR SEQ ID NO:10:
148 (i) SEQUENCE CHARACTERISTICS:
149 (A) LENGTH:12 base pairs
150 (B) TYPE:nucleic acid
151 (C) STRANDEDNESS:double
152 (D) TOPOLOGY:linear
153 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:10:
154
155 ACCGACGTCGGT
156 TGGCTGCAGCCA
157

--> 158 (2) INFORMATION FOR SEQ ID NO:11:
159 (i) SEQUENCE CHARACTERISTICS:
160 (A) LENGTH:6 base pairs
161 (B) TYPE:nucleic acid
162 (C) STRANDEDNESS:double
163 (D) TOPOLOGY:linear
164 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:11:
165
166 ATGATC
167 TACTAG
168

--> 169 (2) INFORMATION FOR SEQ ID NO:12:
170 (i) SEQUENCE CHARACTERISTICS:
171 (A) LENGTH:9 base pairs
172 (B) TYPE:nucleic acid
173 (C) STRANDEDNESS:double
174 (D) TOPOLOGY:linear
175 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:12:
176
177 GCGTGGGCG
178 CGCACCCGC
179

--> 180 (2) INFORMATION FOR SEQ ID NO:13:
181 (i) SEQUENCE CHARACTERISTICS:
182 (A) LENGTH:9 base pairs
183 (B) TYPE:nucleic acid
184 (C) STRANDEDNESS:double
185 (D) TOPOLOGY:linear
186 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:13:
187
188 CAGAACATC
189 GTCTTG TAG
190

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:45:56

INPUT SET: S25541.raw

191 (2) INFORMATION FOR SEQ ID NO:14:
192 (i) SEQUENCE CHARACTERISTICS:
--> 193 (A) LENGTH:8 base pairs
194 (B) TYPE:nucleic acid
195 (C) STRANDEDNESS:double
196 (D) TOPOLOGY:linear
197 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:14:
198
199 TATATAAA
200 ATATATTT
201

202 (2) INFORMATION FOR SEQ ID NO:15:
203 (i) SEQUENCE CHARACTERISTICS:
--> 204 (A) LENGTH:309 base pairs 319 shown
205 (B) TYPE:nucleic acid
206 (C) STRANDEDNESS:single
207 (D) TOPOLOGY:linear
208 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:15:
209
--> 210 GAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGC1
211
212 AGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGG51
213
214 GCCAAACAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCYCAGGGCCAA101
215
216 GAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGAAC151
217
218 CATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTT201
219
220 ATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTGCGCGCTTCTG251
221
--> 222 CTCCCCGAGCTCAATAAAA301
223

invalid format (see seq 5)

incorrect numbering -
show the cumulative
total at the end of
each line. see
1.822(1) of
Sequence Rules

224 (2) INFORMATION FOR SEQ ID NO:16:
225 (i) SEQUENCE CHARACTERISTICS:
--> 226 (A) LENGTH:309 base pairs 326 shown
227 (B) TYPE:nucleic acid
228 (C) STRANDEDNESS:single
229 (D) TOPOLOGY:linear
230 (ix) SEQUENCE DESCRIPTION:SEQ ID NO:16:
231
--> 232 ACGCTTGATCCGGCTACCTGCCCATTGACCACCAAGCGAAACATCGCAT1
233
234 CGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTGATCAGGATGATC51
235
236 TGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTGCGCCAGGCTC101
237
238 AAGGCGCGCATGCCCCGACGGCGAGGATCTCGTCGTGACTTTCTAGAGAAC151
239
240 CATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGCCTT201

invalid format

incorrect numbering

see next page

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:45:57

INPUT SET: S25541.raw

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

--> 264 LC/WORD/USPROSECUTION/ENZ56/SEQUENCE LISTING.10.1.97

--> 265 SEQ ID NO: 1, PAGE 6

266

267 ENZ-56

268

269 ENZ-56

270

271

272

251) incorrect
< insert total
(cumulative)

delete

SEQUENCE VERIFICATION REPORT

PATENT APPLICATION *US/08/822,963*


DATE: 05/05/98
TIME: 14:45:59

INPUT SET: S25541.raw

[illegible]

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION US/08/822,963DATE: 05/05/98
TIME: 14:46:00**INPUT SET: S25541.raw**

Line	Error	Original Text
264	Wrong Nucleic Acid Designator	LC/WORD/USPROSECUTION/ENZ56/SEQUENCE LIST
264	Wrong Nucleic Acid Designator	LC/WORD/USPROSECUTION/ENZ56/SEQUENCE LIST
264	# of Sequences for line conflicts w/ running total	LC/WORD/USPROSECUTION/ENZ56/SEQUENCE LIST
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	Wrong Nucleic Acid Designator	SEQ ID NO: 1, PAGE 6
265	# of Sequences for line conflicts w/ running total	SEQ ID NO: 1, PAGE 6



Notice of Availability of Checker Program

Applicant Aid for Biotechnology Computer Readable Form (CRF) Sequence Listing Submissions

The Patent and Trademark Office (PTO) has developed a computer program, called Checker, that will aid applicants in identifying and correcting errors prior to making submissions for compliance with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (Sequence Rules: 37CFR 1.821 through 1.825).

Final rules were published in the *Federal Register* (55 FR18230) on May 1, 1990, and in the PTO *Official Gazette* (1114 Off.Gaz.PatOffice 29) on May 15, 1990.

Checker is a DOS-based software program that is intended to assist users in determining whether errors may be present in the sequence listings, and is not intended to guarantee that the submission is error-free.

The most current version of the software is available via computer downloading, details are below. Copies on diskette are also available. Updated software versions will not be automatically mailed out; any updates will be announced in the PTO *Official Gazette*.

The software can be accessed/requested from the following locations:

- 1) Dial-up access through the Internet. Location is <ftp://ftp.uspto.gov>
The software is in current directory: pub/checker/
Download all the files. Cost: Free-of-charge
- 3) For diskette copies, mail to: U.S.P.T.O., OEIP, CRYSTAL PARK 3, SUITE 441
WASHINGTON DC 20231

COST FOR DISKETTE IS \$ 25.00

METHOD OF PAYMENT:

Check payable to Commissioner of Patents and Trademarks
VISA/ Mastercard/ Charge- Charges can be faxed to 703-306-2737
PTO Deposit Account

For Further Information, Contact: Arti Shah at 703-308-4212

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.

FILE 'USPAT' ENTERED AT 14:20:28 ON 03 JUN 1998

* WELCOME TO THE *
* U. S. PATENT TEXT FILE *

=> s snrna

L1 36 SNRNA

=> s l1 and vector?

66390 VECTOR?
L2 33 L1 AND VECTOR?

=> s l2 and viral

14281 VIRAL
L3 31 L2 AND VIRAL

=> s l3 and promoter?(5A)snrna

29977 PROMOTER?
36 SNRNA
7 PROMOTER?(5A)SNRNA
L4 6 L3 AND PROMOTER?(5A)SNRNA

=> d l4,1-6,cit,ab

1 5,750,390, May 12, 1998, Method and reagent for treatment of diseases caused by expression of the bcl-2 gene; James D. Thompson, et al., 435/195, 320.1, 325, 336; 536/23.2, 24.5 [IMAGE AVAILABLE]

US PAT NO: 5,750,390 [IMAGE AVAILABLE] L4: 1 of 6

ABSTRACT:

An enzymatic RNA molecule which cleaves bcl.2 mRNA associated with development or maintenance of follicular lymphoma.

2. 5,728,521, Mar. 17, 1998, Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence; Yan Yuan, et al., 435/6, 91.2 [IMAGE AVAILABLE]

US PAT NO: 5,728,521 [IMAGE AVAILABLE] L4: 2 of 6

ABSTRACT:

It has been discovered that any RNA can be targeted for cleavage by RNAase P from eukaryotic cells, for example, human RNAase P, using a suitably designed oligoribonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNAase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. The most efficient EGS with human RNAase P is the EGS in which the anticodon stem and loop was deleted. Modifications can also be made within the T-loop. Methods are also disclosed to randomly select and to express a suitable EGS in vivo

to make a selected RNA target for cleavage by the host cell RNAase P, thus preventing expression of the function of the target RNA. The methods and compositions should be useful to prevent the expression of disease-causing genes in vivo.

3. 5,624,824, Apr. 29, 1997, Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence; Yan Yuan, et al., 435/91.2; 514/44; 536/23.1 [IMAGE AVAILABLE]

US PAT NO: 5,624,824 [IMAGE AVAILABLE]

L4: 3 of 6

ABSTRACT:

It has been discovered that any RNA can be targeted for cleavage by RNAase P from eukaryotic cells, for example, human RNAase P, using a suitably designed oligoribonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNAase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. The most efficient EGS with human RNAase P is the EGS in which the anticodon stem and loop was deleted. Modifications can also be made within the T-loop. Methods are also disclosed to randomly select and to express a suitable EGS in vivo to make a selected RNA a target for cleavage by the host cell RNAase P, thus preventing expression of the function of the target RNA. The methods and compositions should be useful to prevent the expression of disease-causing genes in vivo.

4. 5,624,803, Apr. 29, 1997, In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom; Sarah B. Noonberg, et al., 435/6, 91.1, 320.1; 536/24.1 [IMAGE AVAILABLE]

US PAT NO: 5,624,803 [IMAGE AVAILABLE]

L4: 4 of 6

ABSTRACT:

The present invention encompasses improved methods and materials for the delivering of antisense, triplex, and/or ribozyme oligonucleotides intracellularly, and RNA polymerase III-based constructs termed "oligonucleotide generators" to accomplish the delivery of oligonucleotides. Also encompassed by the present invention are methods for screening oligonucleotide sequences that are candidates for triplex formation.

5. 5,610,052, Mar. 11, 1997, Enzymatic RNA with activity to ras; James D. Thompson, et al., 435/366, 363; 536/23.2, 24.5 [IMAGE AVAILABLE]

US PAT NO: 5,610,052 [IMAGE AVAILABLE]

L4: 5 of 6

ABSTRACT:

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of colon carcinoma.

6. 5,599,704, Feb. 4, 1997, ErbB2/neu targeted ribozymes; James D. Thompson, et al., 435/325, 6, 91.31, 172.3, 320.1, 366; 514/44; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]

US PAT NO: 5,599,704 [IMAGE AVAILABLE]

L4: 6 of 6

ABSTRACT:

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of breast cancer.

=> d kwic,1

SUMMARY:

BSUM(19)

In a third related aspect, the invention features an expression **vector** which includes nucleic acid encoding an enzymatic RNA molecule described above, located in the **vector**, e.g., in a manner which allows expression of that enzymatic RNA molecule within a mammalian cell.

SUMMARY:

BSUM(22)

The . . . is very difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. Delivery of ribozymes by expression **vectors** is primarily feasible using only ex vivo treatments. This limits the utility of this approach. In this invention, an alternative. . .

DETDESC:

DETD(4)

FIG. . . . of a hammerhead motif ribozyme showing stems I, II and III (marked (I), (II) and (III) respectively) interacting with a **viral** target region. The 5' and 3' ends of both ribozyme and target are shown. Dashes indicate base-paired nucleotides.

DETDESC:

DETD(28)

Expression **Vector** While synthetic ribozymes are preferred in this invention, those produced by expression **vectors** can also be used. (See McSwiggen, U.S. Ser. No. 07/884,431, filed May 14, 1992, hereby incorporated by reference herein.) In designing a suitable ribozyme expression **vector** the following factors are important to consider. The final ribozyme must be kept as small as possible to minimize unwanted secondary structure within the ribozyme. A promoter (eg, the human cytomegalovirus immediate early **promoter** or the human U6 **snRNA promoter**) should be chosen to be a relatively strong promoter, and expressible both in vitro and in vivo (e.g., the human. . .

DETDESC:

DETD(29)

A . . . of shorter length can be used to provide good termination and RNA stability. Such hairpins can be inserted within the **vector** sequences to allow standard ribozymes to be placed in an appropriate orientation and expressed with such sequences attached.

DETDESC:

DETD(30)

Poly(A) . . . the 3' end of the ribozyme. These can be provided by either including a poly(A) signal site in the expression **vector** (to signal a cell to add the poly(A) tail in vivo), or by introducing a poly(A) sequence directly into the expression **vector**. In the first approach the signal must be located to prevent unwanted secondary structure formation with other parts of the. . . In the second approach, the poly(A) stretch may reduce in size over time when expressed

in vivo, and thus the **vector** may need to be checked over time. Care must be taken in addition of a poly(A) tail which binds poly(A).

DETDESC:

DETD(69)

Selected . . . of delivery. Routes of administration include intramuscular, aerosol, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal. Expression **vectors** for immunization with ribozymes and/or delivery of ribozymes are also suitable.

DETDESC:

DETD(73)

b. transduction by retroviral **vectors**,

DETDESC:

DETD(78)

At . . . of delivery strategies are useful in the present invention, including: ribozyme modifications, particle carrier drug delivery vehicles, and retroviral expression **vectors**. Unmodified ribozymes, like most small molecules, are taken up by cells, albeit slowly. To enhance cellular uptake, the ribozyme may.

CLAIMS:

CLMS(10)

10. A **vector** comprising a nucleic acid encoding the enzymatic RNA molecule of claim 1 operatively linked to a promoter.

CLAIMS:

CLMS(13)

13. A mammalian cell in vitro comprising a **vector** of claim 10.

=> d kwic,2

US PAT NO: 5,728,521 [IMAGE AVAILABLE]

L4: 2 of 6

DETDESC:

DETD(14)

The . . . next round of selection. After eight cycles of selection, the resulting pool of double-stranded DNAs is cloned into an appropriate **vector** and sequenced.

DETDESC:

DETD(29)

There . . . human or other eucaryotic equivalents thereof, are introduced into the cell at the desired location for cleavage using a suitable **vector** or other method known to those skilled in the art for introduction and expression of a gene in a cell.

DETDESC:

DETD(33)

The . . . RNAase P in any cell, such as the RNAase P of human cells, can be directed to destroy specific messenger, **viral** or other RNAs by the use of an appropriate EGS RNA.

DETD(DESC):

DETD(39)

Any . . . product of an oncogene, such as the ras gene product; where the product is not a normal cell component, a **viral** protein, such as one encoded by an essential gene for HIV replication; or a bacterial protein.

DETD(DESC):

DETD(42)

There . . . two primary mechanisms for delivering the EGS to intracellular RNA that has been targeted for cleavage: diffusion and via a **vector**.

DETD(DESC):

DETD(43)

As . . . to the infected cells are those in which critical RNA sequences are transcribed in the nucleus. Important examples of the **viral** agents that replicate in the cell nucleus include herpes viruses (including herpes simplex virus, varicella-herpes zoster virus, cytomegalovirus, and Epstein-Barr. . .

DETD(DESC):

DETD(44)

Vector-mediated delivery of EGS.

DETD(DESC):

DETD(45)

Preferred **vectors** are **viral vectors** such as the retroviruses which introduce the EGS directly into the nucleus where it is transcribed and released into the. . .

DETD(DESC):

DETD(46)

Methods for using retroviral **vectors** for gene therapy are described in U.S. Pat. Nos. 4,868,116 and 4,980,286, and PCT application PCT/US89/03794 and PCT/US89/00422, the teachings. . .

DETD(DESC):

DETD(47)

Defective retroviral **vectors**, which incorporate their own RNA sequence in the form of DNA into the host chromosome, can be engineered to incorporate. . .

DETD(DESC):

DETD(48)

The . . . the introduction of specific genetic sequences into human cells involves the use of RNA-containing retroviruses which serve as vehicles or **vectors** for high efficiency gene transfer into human cells.

DETDESC:

DETD(49)

RNAase . . . cells and subsequent partial cytoablation. The removed cells can be treated in the laboratory with appropriate EGS compositions (via appropriate **viral vectors**, such as defective **viral vectors**) and then restored to the same individual. The treated cells will develop in the patient into mature hematopoietic cells, including.

DETDESC:

DETD(51)

In . . . and possibly to cure, HIV infection, and related diseases of white blood cells which are subject to transformation by retroviral **vectors** carrying EGS. Particular examples of diseases that may be treated using EGS to target RNA for cleavage by RNAase P. . .

DETDESC:

DETD(55)

A preferred composition is a topical composition, for example, for application to a **viral** lesion such as that produced by herpes simplex virus. These will generally contain between 1 μ M and 1 mM oligonucleotide/unit. . . locally for release of EGS. Still another preferred composition is a solution or suspension of the EGS in an appropriate **vector** in combination with conventional pharmaceutical vehicles are employed for parenteral compositions, such as an aqueous solution for intravenous injection or. . .

DETDESC:

DETD(68)

The . . . with CAT mRNA. The EGS.sup.CAT (Sequence ID No. 8) fused upstream with a T7 promoter was cloned into a pUC19 **vector**. The EGS.sup.CAT RNA (Sequence ID No. 8) was prepared through in vitro transcription with T7 RNA polymerase. A HindIII-BamHI DNA. . .

DETDESC:

DETD(76)

In . . . the EGS can function in vivo, the EGS.sup.CAT sequence (Sequence ID No. 8) was inserted downstream of a mouse U6 **snRNA** gene **promoter** in a BLUESCRIPT.TM. (Stratagene, La Jolla, Calif.) **vector** forming pEGS.sup.CAT. The EGS.sup.CAT sequence (Sequence ID No. 8) can be transcribed by RNA polymerase III and the transcription can. . .

DETDESC:

DETD(94)

After eight cycles of selection and the resulting pool of double-stranded DNAs were cloned into the BLUESCRIPT.TM. **vector**

(Stratagene, La Jolla, Calif.) **vector**. Eighteen plasmid DNAs were sequenced using Sequencer 2.0 (U.S. Biochemicals, Cleveland, Ohio).

DETDESC:

DETD(124)

Inhibition of **viral** mRNA expression with human ribonuclease P.

DETDESC:

DETD(125)

Herpes simplex virus was used to demonstrate that EGS can be used to target a **viral** gene in vivo to inhibit **viral** replication. Herpes simplex viruses are DNA-containing viruses that infect cells, induce synthesis of messenger RNAs, which are transcribed to produce enzymes related to DNA synthesis and breakdown: including thymidine kinase, DNA polymerase and a DNA exonuclease, and **viral** DNA and **viral** structural proteins are made and assembled into infectious **viral** particles. The structure and organization of the herpes simplex virus genome is known, for example, as reported by Roizman, Cell, . . .

DETDESC:

DETD(127)

Cell lines and EGS expression **vectors** were then constructed. Five cell lines were constructed by transfecting plasmid DNAs into human 143TK-cells, which can be obtained from. . .

DETDESC:

DETD(131)

Cells . . . then infected with herpes simplex virus using a multiplicity of infection (MOI) of 1 to 1.5 (1 to 1.5 million **viral** particles/1 million cells) in order to resemble a natural infection with virus. RNA was harvested at 4, 8 and 12. . . late genes U.sub.S 10 and U.sub.S 11. The probe is selected to assure the detection of a high level of **viral** mRNA expression over the entire cycle of **viral** infection.

=> d kwic,3

US PAT NO: 5,624,824 [IMAGE AVAILABLE]

L4: 3 of 6

DETDESC:

DETD(14)

The . . . next round of selection. After eight cycles of selection, the resulting pool of double-stranded DNAs is cloned into an appropriate **vector** and sequenced.

DETDESC:

DETD(29)

There . . . human or other eucaryotic equivalents thereof, are introduced into the cell at the desired location for cleavage using a suitable **vector** or other method known to those skilled in the art for introduction and expression of a gene in a cell.

DETDESC:

DETD(33)

The . . . RNAase P in any cell, such as the RNAase P of human cells, can be directed to destroy specific messenger, **viral** or other RNAs by the use of an appropriate EGS RNA.

DETDESC:

DETD(39)

Any . . . product of an oncogene, such as the ras gene product; where the product is not a normal cell component, a **viral** protein, such as one encoded by an essential gene for HIV replication; or a bacterial protein.

DETDESC:

DETD(42)

There . . . two primary mechanisms for delivering the EGS to intracellular RNA that has been targeted for cleavage: diffusion and via a **vector**.

DETDESC:

DETD(43)

As . . . to the infected cells are those in which critical RNA sequences are transcribed in the nucleus. Important examples of the **viral** agents that replicate in the cell nucleus include herpesviruses (including herpes simplex virus, varicella-herpes zoster virus, cytomegalovirus, and Epstein-Barr virus),. . .

DETDESC:

DETD(44)

Vector-mediated delivery of EGS.

DETDESC:

DETD(45)

Preferred **vectors** are **viral vectors** such as the retroviruses which introduce the EGS directly into the nucleus where it is transcribed and released into the. . .

DETDESC:

DETD(46)

Methods for using retroviral **vectors** for gene therapy are described in U.S. Pat. Nos. 4,868,116 and 4,980,286, and PCT application PCT/US89/03794 and PCT/US89/00422, the teachings. . .

DETDESC:

DETD(47)

Defective retroviral **vectors**, which incorporate their own RNA sequence in the form of DNA into the host chromosome, can be engineered to incorporate. . .

DETDESC:

DETD(48)

The . . . the introduction of specific genetic sequences into human cells involves the use of RNA-containing retroviruses which serve as vehicles or **vectors** for high efficiency gene transfer into human cells.

DETD(DESC):

DETD(49)

RNAase . . . cells and subsequent partial cytoablation. The removed cells can be treated in the laboratory with appropriate EGS compositions (via appropriate **viral vectors**, such as defective **viral vectors**) and then restored to the same individual. The treated cells will develop in the patient into mature hematopoietic cells, including.

DETD(DESC):

DETD(51)

In . . . and possibly to cure, HIV infection, and related diseases of white blood cells which are subject to transformation by retroviral **vectors** carrying EGS. Particular examples of diseases that may be treated using EGS to target RNA for cleavage by RNAase P. . .

DETD(DESC):

DETD(55)

A preferred composition is a topical composition, for example, for application to a **viral** lesion such as that produced by herpes simplex virus. These will generally contain between 1 .mu.M and 1 mM oligonucleotide/unit. . . locally for release of EGS. Still another preferred composition is a solution or suspension of the EGS in an appropriate **vector** in combination with conventional pharmaceutical vehicles are employed for parenteral compositions, such as an aqueous solution for intravenous injection or. . .

DETD(DESC):

DETD(68)

The . . . changed to make base-pairs with CAT mRNA. The EGS.sup.CAT fused upstream with a T7 promoter was cloned into a pUC19 **vector**. The EGS.sup.CAT RNA was prepared through in vitro transcription with T7 RNA polymerase. A HindIII-BamHI DNA fragment of the CAT. . .

DETD(DESC):

DETD(76)

In . . . the EGS can function in vivo, the EGS.sup.CAT Sequence ID No. 8 sequence was inserted downstream of a mouse U6 **snRNA** gene **promoter** in a BLUESCRIPT.sup.TM (Stratagene, La Jolla, Calif.) **vector** forming pEGS.sup.CAT. The EGS.sup.CAT Sequence ID No. 8 sequence can be transcribed by RNA polymerase III and the transcription can. . .

DETD(DESC):

DETD(94)

After eight cycles of selection and the resulting pool of double-stranded DNAs were cloned into the BLUESCRIPT.SM vector (Stratagene, La Jolla, Calif.) vector. Eighteen plasmid DNAs were sequenced using Sequenase 2.0 (U.S. Biochemicals, Cleveland, Ohio).

DETDESC:

DETD(125)

Herpes simplex virus was used to demonstrate that EGS can be used to target a **viral** gene in vivo to inhibit **viral** replication. Herpes simplex viruses are DNA-containing viruses that infect cells, induce synthesis of messenger RNAs, which are transcribed to produce. . . enzymes related to DNA synthesis and breakdown: including thymidine kinase, DNA polymerase and a DNA exonuclease, and vital DNA and **viral** structural proteins are made and assembled into infectious **viral** particles. The structure and organization of the herpes simplex virus genome is known, for example, as reported by Roizman, Cell, . . .

DETDESC:

DETD(127)

Cell lines and EGS expression **vectors** were then constructed. Five cell lines were constructed by transfecting plasmid DNAs into human 143TK-cells, which can be obtained from. . .

DETDESC:

DETD(131)

Cells . . . then infected with herpes simplex virus using a multiplicity of infection (MOI) of 1 to 1.5 (1 to 1.5 million **viral** particles/1 million cells) in order to resemble a natural infection with virus. RNA was harvested at 4, 8 and 12. . . late genes U.sub.s 10 and U.sub.s 11. The probe is selected to assure the detection of a high level of **viral** mRNA expression over the entire cycle of **viral** infection.

CLAIMS:

CLMS(9)

9. . . . RNA selected from the group consisting of RNA complementary to oncogenes, RNA complementary to tumor suppressor genes, RNA complementary to **viral** genes and RNA **viral** genes, and cellular mRNAs which encode proteins selected from the group consisting of enzymes, hormones, cofactors, antibodies, and growth factors.

CLAIMS:

CLMS(11)

11. The composition of claim 1 wherein the external guide sequence is in a **vector** for introducing the external guide sequence into a cell containing the RNA targeted for cleavage.

CLAIMS:

CLMS(12)

12. The composition of claim 11 wherein the **vector** is a retroviral **vector**.

CLAIMS:

15. . . . RNA selected from the group consisting of RNA complementary to oncogenes. RNA complementary to tumor suppressor genes, RNA complementary to **viral** genes and RNA **viral** genes, and cellular mRNAs which encode proteins selected from the group consisting of enzymes, hormones, cofactors, antibodies, and growth factors.

CLAIMS:

CLMS (16)

16. The method of claim 13 further comprising providing the external guide sequence in a **vector** for introducing the external guide sequence into a cell containing the RNA targeted for cleavage.

=> d fro,1

US PAT NO: 5,750,390 [IMAGE AVAILABLE] L4: 1 of 6
 DATE ISSUED: May 12, 1998
 TITLE: Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
 INVENTOR: James D. Thompson, Boulder, CO
 Kenneth G. Draper, Boulder, CO
 ASSIGNEE: Ribozyme Pharmaceuticals, Inc., Boulder, CO (U.S. corp.)
 APPL-NO: 07/936,421
 DATE FILED: Aug. 26, 1992
 INT-CL: [6] C12N 15/10
 US-CL-ISSUED: 435/195, 320.1, 325, 336; 536/23.2, 24.5
 US-CL-CURRENT: 435/195, 320.1, 325, 336; 536/23.2, 24.5
 SEARCH-FLD: 514/44; 435/320.1, 199, 240.1, 172.3; 935/44, 46; 536/23.2
 REF-CITED:

FOREIGN PATENT DOCUMENTS

9115580	10/1991	World Intellectual Property Organization
9118624	12/1991	World Intellectual Property Organization
9118625	12/1991	World Intellectual Property Organization
9118913	12/1991	World Intellectual Property Organization
9200080	1/1992	World Intellectual Property Organization

OTHER PUBLICATIONS

Tseng et al (1994) Cancer Gene Therapy 1, 65-71.
 "Oncogenes", G.M. Cooper, Jones and Bartlett Publishers, Boston 1990, pp. 97-108 and pp. 141-159.
 Harrsims Principles of Internal Medicine vol. I, Isselbacher et al, eds, 1994, pp. 374-380 and pp. 1116-1331.
 Seto et al., "Alternative promoters and exons, somatic . . . fusion gene in lymphoma", The EMBO Journal vol. 7, No. 1, 123-131, 1988.
 Hua et al., "Mechanism of bcl-2 activation in human follicular lymphoma", Oncogene 1990, 5:233-235.
 Hampel et al., "RNA Catalyst for Cleaving Specifiec RNA Sequences", filed Sep. 20, 1989, which is a Continuation-in-Part of U.S. Serial No. 07/247,100 filed Sep. 20, 1988.
 Perrotta and Been, 31 Biochemistry 16, 1992.
 Hampel and Tritz, 28 Biochemistry 4929, 1989.
 Hampel et al., 18 Nucleic Acids Research 299, 1990.
 Weerasinghe et al., 65 Journal of Virology 5531, 1991.
 Mamone et al., "Design of Hammerhead Ribozymes Targeted to Sequences in

HIV, HSV, and the RABNF Gene", Abstract of Keystone, CO (May 27, 1992).

Pavco et al., "Regulation of Self-Splicing Reactions by Antisense RNA", Abstract of Keystone, CO (May 27, 1992).

Haseloff and Gerlach, 334 Nature 585, 1988.

Guerrier-Takada et al., 35 Cell 849, 1983.

Sarver et al (1990) Science 247, 1222-1225.

Cleary et al (1986) Cell 47,19-28.

ART-UNIT: 189

PRIM-EXMR: Deborah Crouch

LEGAL-REP: Lyon & Lyon LLP

ABSTRACT:

An enzymatic RNA molecule which cleaves bcl.2 mRNA associated with development or maintenance of follicular lymphoma.

13 Claims, 1 Drawing Figures

20. 5,324,643, Jun. 28, 1994, Method of conferring resistance to retroviral infection; Wilson Greatbatch, et al., 435/91.32, 91.1, 91.3, 172.3, 372; 536/23.1; 935/3, 6, 34, 70 [IMAGE AVAILABLE]

21. 5,166,057, Nov. 24, 1992, Recombinant negative strand RNA virus expression-systems; Peter Palese, et al., 435/69.1, 172.3, 194, 235.1, 320.1; 935/32, 34, 57 [IMAGE AVAILABLE]

=> d kwic,21

US PAT NO: 5,166,057 [IMAGE AVAILABLE]

L6: 21 of 21

SUMMARY:

BSUM(82)

Animal . . . case of brome mosaic virus (BMV), a positive strand RNA plant virus, SP6 transcripts have been used to identify the **promoter** as a 134 nt **tRNA**-like 3' terminus (Dreher, and Hall, 1988, J. Mol. Biol. 201: 31-40). Polymerase recognition and synthesis were shown to be dependent. . .

SUMMARY:

BSUM(89)

As . . . RNA dependent RNA-polymerase and allow for complementation. Additionally, a non-virus dependent replication system for influenza virus is also described. Vaccinia **vectors** expressing influenza virus polypeptides were used as the source of proteins which were able to replicate and transcribe synthetically derived. . .

DRAWING DESC:

DRWD(20)

FIG. . . . were infected with mixtures of recombinant vaccinia viruses (Smith et al., 1986) at an M.O.I. of approximately 10 for each **vector**. After 1.5 hours, synthetic IVACAT-1 RNP was transfected into the virus-infected cells as described (Lutjyes et al., 1989). Cells were. . . no helper virus infection; 3-RNP transfection, no helper virus; 4-RNP transfection, influenza virus as helper; Lanes 5-11-RNP transfection, vaccinia virus **vectors** as helper viruses express the indicated influenza virus proteins.

DRAWING DESC:

DRWD(21)

FIG. 20A-C. Test of various cell lines. A) Cells were infected with vaccinia **vectors** expressing the PB2, PB1 and PA proteins (Lanes 1,3,5,7) or the PB2, PB1, PA and NP proteins (Lanes 2,4,6,8), transfected. . .

DETDESC:

DETD(44)

Alternatively, . . . virus in accordance with the invention. To this end, the influenza virus polymerase proteins may be expressed in any expression **vector**/host cell system, including but not limited to **viral** expression **vectors** (e.g., vaccinia virus, adenovirus, baculovirus, etc.) or cell lines that express the polymerase proteins (e.g., see Krystal et al., 1986, . . . with influenza virus, synthetic RNP's are replicated in cells through the action of influenza virus proteins expressed by recombinant vaccinia **vectors**. In this way we show that the only influenza virus proteins essential for transcription and replication of RNP are the. . .

DETDESC:

DETD(49)

Synthetic . . . in viral RNAs. An additional area of great interest concerns the development of the influenza virus system as a vaccine **vector**.

DETDESC:

DETD(53)

In this regard, the use of genetically engineered influenza virus (**vectors**) for vaccine purposes may require the presence of attenuation characteristics in these strains. Current live virus vaccine candidates for use. . .

DETDESC:

DETD(111)

The . . . insert were cut with EcoRI and BglII. The fragments were purified from acrylamide gel and cloned together into the pPHV **vector** which had been cut with XbaI and BglII. After transformation, white colonies were grown, analysed by endonuclease digestion and selected. .

DETDESC:

DETD(116)

pIVACAT1 . . . strand). Oligonucleotides were synthesized on an Applied Biosystems DNA synthesizer. These 5' and 3' constructs were ligated into pUC19 shuttle **vectors** digested with XbaI and EcoRI, grown up, cut out with EcoRI/BglII (5' region) and XbaI/EcoRI (3' region) and ligated into. . .

DETDESC:

DETD(141)

The . . . genomes. Furthermore, this technology may allow for the construction of infectious chimeric influenza viruses which can be used as efficient **vectors** for gene expression in tissue culture, animals or man.

DETDESC:

DETD(161)

In . . . vaccinia viruses (Smith et al., 1987, Virology, 160: 336-345) and transfected one hour later with the IVACAT-1 RNP. Mixtures of **vectors** expressing the three polymerases (PB2, PB1 and PA) and the

nucleoprotein were used. Replication and transcription of the synthetic RNP. . . recombinant vaccinia viruses. CAT activity present in this sample as well as in cells infected with all four vaccinia **vectors** (FIG. 19, lanes 8 and 10). Cells expressing any of the subsets of these four proteins did not produce detectable. . . is necessary and sufficient for RNP expression and replication in this system. The levels of CAT activity obtained in vaccinia **vector**-infected cells are reproducibly higher than in cells infected with influenza as helper virus. The most probable explanation for this is. . .

DETDESC:

DETD(162)

A . . . using MDBK, Hela, 293 and L cells. In each case, no CAT activity was observed when cells were infected with **vectors** that express only the 3 polymerase proteins but significant CAT activity was obtained if the additional vaccinia-**vector** inducing NP expression was also added.

DETDESC:

DETD(163)

Previously, . . . Natl. Acad. Sci. USA 83: 2709-2713; Li et al., 1989, Virus Research 12: 97-112). Since replication through recombinant vaccinia virus **vectors** is dependent only on these proteins, it was conceivable that this cell line may be able to amplify and express. . . proteins supported the expression of CAT (FIG. 20B, lane 2). FIG. 20B, lane 3 shows that the minimum mixture of **vectors** needed to induce CAT activity in 3PNP-4 cells are those expressing only the PB1 and PA proteins. Therefore, the steady. . .

DETDESC:

DETD(164)

Since . . . detectable levels of protein in influenza virus infected cells. Accordingly, we used this mutant RNA to examine whether the vaccinia **vector**-expressed influenza proteins induces CAT activity solely through primary transcription of input RNP or can allow for amplification through replication and. . .

DETDESC:

DETD(166)

This recombinant vaccinia **vector** dependent scheme possesses a number of advantages over the use of influenza virus infection to drive the replication of synthetic. . . NP proteins are required for the detection of expressed protein and for replication of RNP. Another advantage of this vaccinia **vector** driven replication scheme is that since the influenza polymerase proteins are expressed from cDNA integrated into the vaccinia virus, the. . .

=> d kwic,20

US PAT NO: 5,324,643 [IMAGE AVAILABLE]

L6: 20 of 21

ABSTRACT:

In . . . or more of the infection processes including retroviral replication and assembly into infective viral particles. The method involves introducing a **vector** into a host cell, wherein the **vector** comprises a polynucleotide which directs transcription, within

the host cell, of RNA which is a) complementary or homologous, depending on. . .

SUMMARY:

BSUM(27)

In . . . genetic resistance to retroviral infection upon a host cell is disclosed. The method involves transforming the host cell with a **vector** comprising a polynucleotide directing transcription within the host cell of RNA which (a) is complementary or corresponding to a nucleic. . . replication of the retrovirus when the host cell is infected. The method also involves transforming the host cell with a **vector** comprising a polynucleotide directing transcription within the host cell of RNA which corresponds to sequences which represent a small portion. . .

SUMMARY:

BSUM(28)

Cells upon which resistance to infection is to be conferred, are transformed with a polynucleotide via a **vector**. "Transformation" or "transformed", as those terms are used throughout this specification and the appended claims, is intended to cover any. . .

SUMMARY:

BSUM(33)

The polynucleotide is transformed via a **vector**. Any known **vectors**, including without limitation, **viral vectors**, retroviral **vectors** and plasmids, may be used. Preferably the **vector** is a plasmid. The **vector** can include a promoter and/or a terminator for regulation of the polynucleotide. The final construct (**vector** and polynucleotide) can include one or more promoters and/or terminators including those made part of the polynucleotide as described above. The **vector** can also include a selectable marker for detection and isolation of successfully transformed cells including without limitation antibiotic resistance to. . .

SUMMARY:

BSUM(35)

Nucleic acid constructs, including a polynucleotide as previously described, are also disclosed. The construct can include a **vector** as previously described.

DRAWING DESC:

DRWD(22)

FIG. 20 is a schematic illustration of the RSV **vector** family.

DETDESC:

DETD(4)

The . . . as used herein, refers to one or more nucleotide sequences (polynucleotides or genes) that are inserted into one of the **vectors** chosen from the group of **vectors** including a virus, retrovirus, or plasmid. The polynucleotide sequences described herein are preferably DNA, but could include RNA or a combination thereof, and are integrated into the appropriate **vector** by ligation or other similar techniques.

With reference to Table 1, there are listed sequences which are illustrative of the polynucleotides of the nucleic acid constructs which are inserted into the appropriate **vector**.

DETDESC:

DETD(12)

A **vector** was used to introduce the nucleic acid constructs into a cell. "**Vector**" specifically refers to a flanking nucleic acid sequence which will allow the synthetic polynucleotide to be introduced into a cell and then either inserted into a chromosome or replicated autonomously. Certain **vectors**, e.g., plasmids, may also be used as a means to amplify the constructs of the present invention. The plasmids pRSVneo, pSV2gpt, pSV2neo, pUC19, and pRSVgpt were used as **vectors** for the preferred constructs of the present invention. Plasmids are circular pieces of DNA. They generally have a bacterial origin. . . a marker gene which confers resistance to ampicillin. Plasmid pRSVgpt has a marker gene which confers resistance to xanthine. Other **vectors**, including without limitation other plasmids, viruses and retroviruses can alternatively be used in practicing the present invention. The plasmids used. . .

DETDESC:

DETD(14)

Recombinant . . . signifies plasmid, "GB" signifies the plasmid was constructed by Greatbatch GenAid, and "neo" signifies the selectable marker in the RSV **vector** family. In constructing recombinant PRSV neo **vectors**, one or more polynucleotides comprising a nucleic acid construct was inserted at either the HindIII restriction site (hereinafter HindIII construct). . . is designated pGB-neo-B1 (FIG. 18) and in the opposite orientation, pGB-neo-B2 (FIG. 19). Refer to FIG. 20 illustrating the RSV **vector** family. The figures show two illustrations for each restriction site because the nucleic acid constructs were cloned into the plasmids. . .

DETDESC:

DETD(18)

An effective method of delivering the **vector** DNA into the target cell is required if high efficiency transformation is to be achieved. Transformation of potential host cells. . .

DETDESC:

DETD(21)

The . . . regulation of the amount of RNA produced simply by regulating the number of copies of the gene inserted into the **vector**. Further, Pol III promoters tend to be more or less universal in their expression and should function equally well in. . .

DETDESC:

DETD(22)

The . . . upstream region, the transcription initiating region, "Box A" and "Box B" can be taken directly from any highly active, natural **tRNA**. A **tRNA promoter** sequence which has been shown to be particularly strong is the Glu tRNA gene, in mouse. The Glu tRNA gene has the advantage that it is straightforward to use as an active **promoter** and the short **tRNA** sequence which will be transcribed should not have

any effect on the activity of the nucleic acid construct

DETDESC:

DETD(23)

Another promoter sequence could involve upstream sequences from the **promoter** coming from a natural **tRNA** gene such as Glu tRNA, while transcriptional initiation sequences "Box A", Box B", and all intervening sequences could be supplied. . . This has the advantage of economy and size which will facilitate synthesis and will allow maximum number of polynucleotides per **vector**. In addition, this promoter begins transcription precisely at the 5' end of the nucleic acid construct and ends transcription within. . .

DETDESC:

DETD(27)

To . . . The plasmid designation as previously described indicates that these nucleic acid sequences were cloned into the Hind site of the **vector**. Plasmid #17 was selected to be used in transforming cells, and the resultant transformed cells 5-1 were chosen to be. . . in FIG. 23. The plasmid designation indicates that these nucleic acid sequences were cloned into the Hind site of the **vector**. Plasmid #16 was selected to be used in transforming cells, and the resultant transformed cells, 4 -2, were chosen to. . . illustrated in FIG. 23. Plasmid designation indicates that these nucleic acid sequences were cloned into the Bam site of the **vector**, plasmid #8 was selected to be used in transforming cells, and the resultant transformed cells, 3-1, were chosen to be. . .

DETDESC:

DETD(32)

Another . . . present invention is a synthesized double-stranded DNA sequence operatively linked to the SV40 early promoter sequence contained within a retroviral **vector**. The nucleic acid construct (Anti-PBS Gene Construct, as shown in FIG. 9) is transcribed into an anti-sense RNA molecule which. . .

DETDESC:

DETD(33)

Copies . . . cut to blunt ends using Nae I and Sma I. The nucleic acid constructs were then cloned into the retroviral **vector** LNSX (a gift of Dr. D. Miller, Seattle) which had been previously cut with Stu I. The inserts have been. . . Transfectants were selected for by neomycin resistance with the presence of G418 in the tissue culture medium, since the retroviral **vector** contains the neo gene.

DETDESC:

DETD(34)

To evaluate the resistance to FeLV of a cell line containing the nucleic acid construct in a retroviral **vector**, confluent monolayers of normal and transfected mink cells were challenged with the EECC strain of FeLV. Inhibition of FeLV replication. . .

DETDESC:

DETD(35)

Although this embodiment describes transfection of the lung cells with the retroviral **vector**, feline cat embryo cells (NCE) have been successfully infected with retroviral **vector** which had been generated from a commercially available packaging cell line. Since NCE cells containing the retroviral **vector** with insert are selected for in the presence of G418 in the culture media, these cells could be used as.

CLAIMS:

CLMS (1)

We . . .

consisting of retroviral replication, reverse transcription, and translation, said method comprising:

Introduction into said host cell in vitro of a **vector** comprising a polynucleotide which is transcribed to RNA, within said host cell, said RNA is complementary to a nucleic acid. . .

CLAIMS:

CLMS (4)

4. The method of claim 1, wherein said **vector** is selected from the group consisting of a **viral vector**, a retroviral **vector** and a plasmid.

CLAIMS:

CLMS (5)

5. The method of claim 4, wherein said **vector** is a plasmid.

CLAIMS:

CLMS (7)

7. The method of claim 4, wherein said **vector** further comprises a first promoter which controls transcription of said RNA within said host cell.

CLAIMS:

CLMS (8)

8. The method of claim 4, wherein said **vector** further comprises a first terminator which controls termination of transcription of said RNA within said host cell.

CLAIMS:

CLMS (9)

9. The method of claim 4, wherein said **vector** further comprises a marker for selection of transformed cells.

CLAIMS:

CLMS (14)

14. . . . the group consisting of retroviral replication, reverse transcription, and translation, said construct comprising a polynucleotide which when introduced by a **vector** into the host cell

in vitro results in transcription of the polynucleotide into RNA complementary to the nucleic acid sequences. . .

CLAIMS:

CLMS (17)

17. The nucleic acid construct of claim 14, wherein said **vector** is selected from the group consisting of a **viral vector**, a retroviral **vector** and a plasmid.

CLAIMS:

CLMS (18)

18. The nucleic acid construct of claim 17, wherein said **vector** is a plasmid.

CLAIMS:

CLMS (19)

19. The nucleic acid construct of claim 17, wherein said **vector** further comprises a first promoter which controls transcription of said RNA within said host cell, and a first terminator which. . .

CLAIMS:

CLMS (20)

20. The nucleic acid construct of claim 17, wherein said **vector** further comprises a marker for selection of transformed cells.

CLAIMS:

CLMS (25)

25. An RNA molecule, produced from the transcription of a polynucleotide of a **vector** which has been introduced into a host cell in vitro, said RNA molecule (a) confers resistance to retroviral infection upon. . .

CLAIMS:

CLMS (26)

26. The RNA molecule of claim 25, wherein said **vector** further comprises a first promoter which controls transcription of said RNA within said host cell.

CLAIMS:

CLMS (27)

27. The RNA molecule of claim 25, wherein said **vector** further comprises a first terminator which controls termination of transcription of said RNA within said host cell.

CLAIMS:

CLMS (28)

28. The RNA molecule of claim 25, wherein said **vector** further comprises a marker for selection of transformed cells.